OptMed
Private Company
Funding information not available
Overview
OptMed is a private medical device company founded in 2005 and headquartered in Irvine, California, focusing on revolutionizing tissue adhesion and protection. Its core innovation is an industry-first methylidene malonate (MM) platform, which enables the creation of biocompatible, high-strength, and flexible medical adhesives and sealants. The company's initial target markets are ophthalmology (e.g., corneal shields, wound closure) and advanced wound care, addressing significant unmet needs for alternatives to sutures and traditional dressings. As a private entity, OptMed likely relies on venture funding and partnerships to advance its technology through development and regulatory pathways toward commercialization.
Technology Platform
Proprietary methylidene malonate (MM) chemistry for creating biocompatible, high-strength, flexible medical adhesives and skin protectants.
Opportunities
Risk Factors
Competitive Landscape
OptMed competes in the medical adhesive and sealant space against large, diversified medtech companies (e.g., J&J, Baxter) and specialized firms. Its success depends on demonstrating clear advantages over existing products like sutures, staples, and cyanoacrylate-based adhesives in terms of safety, strength, and ease of use.